News | Radial Access | June 15, 2017

No Difference in Adverse Events When Comparing Anticoagulants

NCDR report compares outcomes using bivalirudin, heparin in STEMI patients

radial access, transradial access trial using anticoagulants

June 15, 2017 — In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study published in May in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.

Using data from the National Cardiovascular Data Registry CathPCI Registry, researchers examined the records of 67,368 patients from 1,584 sites between 2009 to 2015 with STEMI who underwent primary PCI via radial access. Of these patients, 29,660 received bivalirudin and 37,708 received heparin. The groups did not differ substantially in mean age (60.3 and 60.4, respectively) or percentage of men (74.9 and 75 percent, respectively).

The researchers adjusted for multiple variables, including a propensity score reflecting the probability of receiving bivalirudin to account for patient differences between groups. After these adjustments, the odds ratio of the composite endpoint of death, myocardial infarction or stroke for bivalirudin versus heparin was not statistically significant (0.95); the odds ratio for acute stent thrombosis was 2.11 for bivalirudin versus heparin. Major bleeding rates were not significantly different.

Ion S. Jovin, M.D., FACC, the study’s lead author and medical director of the cardiac catheterization laboratories at McGuire Veterans Affairs Medical Center and associate professor of medicine at Virginia Commonwealth University, said that the study’s results are consistent with data from contemporary studies of patients with acute coronary syndrome and STEMI.

“Our sensitivity analysis provides some insights into direct comparisons of bivalirudin and heparin when GPIIb/IIIa inhibitors are forced out of the equation and suggests that in the direct comparison bivalirudin may have superior outcomes,” Jovin said. “However, our study showed that in the real world over a third of the patients with STEMI undergoing transradial PCI who receive heparin and about a fifth of patients who receive bivalirudin also receive GPIIb/IIIa inhibitors.”

The authors suggested that a randomized trial in patients treated exclusively via transradial primary PCI and anticoagulated with bivalirudin versus heparin as well as a cost-effectiveness analysis comparing heparin versus bivalirudin would help practitioners and hospitals make better decisions regarding anticoagulation in these patients.

For more information: JACC.org


Related Content

News | Radial Access

May 19, 2022 — Initial findings from the Distal versus Proximal Radial Artery Access for Cardiac Catheterization and ...

Home May 19, 2022
Home
Videos | Radial Access

Arnold Seto, M.D., MPA, FSCAI, chief of cardiology, Long Beach Veterans Affairs Medical Center and director ...

Home May 06, 2021
Home
News | Radial Access | Dave Fornell, Editor

April 28, 2021 — A new study reveals the use of a potassium ferrate hemostatic patch (PFHP) reduces the time to ...

Home April 28, 2021
Home
Videos | Radial Access

Jordan G. Safirstein, M.D., FACC, FSCAI, director of transradial catheterization for Atlantic Health System’s Morristown ...

Home October 07, 2020
Home
Videos | Radial Access

Atlantic Health System’s Morristown Medical Center has opened one of the region’s first radial lounges in its Gagnon ...

Home September 11, 2020
Home
News | Radial Access

August 25, 2020 – Atlantic Health System’s Morristown Medical Center has opened one of the region’s first radial lounges ...

Home August 25, 2020
Home
Feature | Radial Access | Dave Fornell, Editor

Transradial access for percutaneous coronary intervention (PCI) in the United States has grown rapidly over the past 20 ...

Home February 14, 2020
Home
News | Radial Access

January 15, 2020 — The Society for Cardiovascular Angiography and Interventions (SCAI) released an updated expert ...

Home January 15, 2020
Home
News | Radial Access

December 30, 2019 — Merit Medical Systems Inc., a leading manufacturer of proprietary devices used primarily in ...

Home December 30, 2019
Home
Feature | Radial Access | Enrique Flores, M.D., RPVI

Interest in distal radial artery access (DRA) is growing rapidly. Among the benefits of DRA are the low risk of entry ...

Home November 21, 2019
Home
Subscribe Now